17 September, 2026
In a landmark legislative development, Members of the European Parliament (MEPs) have officially adopted the Public Health Committee’s comprehensive report on cardiovascular diseases (CVD). This pivotal vote marks a significant shift in the European Union’s approach to non-communicable diseases (NCDs), moving away from siloed treatments toward an integrated, holistic framework. By prioritizing prevention, early detection, and cross-disease cooperation, the Parliament has signaled its commitment to addressing the leading causes of mortality across the continent.
The report serves as the legislative response to the European Commission’s "Safe Hearts Plan," a strategic initiative designed to harmonize cardiovascular care standards across member states. Central to this new policy is the formal recognition by the European Parliament that cardiovascular and respiratory health are inextricably linked, necessitating a unified diagnostic and therapeutic approach.
Main Facts: A Unified Front Against NCDs
The newly adopted report outlines a multi-faceted roadmap for tackling the burden of cardiovascular disease. While heart-related ailments have long been a primary focus of EU health policy, the inclusion of respiratory health—specifically chronic obstructive pulmonary disease (COPD) and obstructive sleep apnoea—represents a sophisticated evolution in health governance.
Key takeaways from the adoption include:
- Integrated Care Pathways: A move toward "one-stop" diagnostic processes where patients at risk for cardiovascular issues are simultaneously screened for underlying respiratory complications.
- Holistic Prevention: A commitment to tackling shared risk factors, such as air pollution, smoking, and sedentary lifestyles, which act as common catalysts for both heart and lung disease.
- Standardized Screening: A mandate to incorporate respiratory function assessments into existing cardiovascular risk-stratification models, particularly for high-risk demographics.
For the European Respiratory Society (ERS), this vote is not merely a policy win; it is a long-awaited validation of clinical evidence that suggests these conditions frequently coexist, compounding the morbidity and mortality rates of millions of European citizens.
Chronology: The Path to Policy Integration
The journey toward this legislative milestone has been defined by years of advocacy and evolving clinical understanding.
- Early 2025: The European Commission unveils the "Safe Hearts Plan," a broad-reaching proposal intended to reduce the incidence of cardiovascular disease by 20% by 2030. While the plan was well-received, critics noted it initially lacked sufficient depth regarding respiratory comorbidities.
- Q3 2025: The European Parliament’s Public Health Committee begins extensive consultations with scientific bodies, including the ERS and the European Lung Foundation (ELF).
- Early 2026: Draft reports are circulated among MEPs. The ERS launches a targeted advocacy campaign, lobbying for the inclusion of standardized lung function testing within cardiovascular screenings.
- Mid-2026: "EU Screening Week" serves as a catalyst for awareness, with the ERS demonstrating the efficacy of integrated health checks in real-world settings.
- 17 September, 2026: The European Parliament adopts the committee’s final report, officially embedding the "integrated approach" into the legislative framework of the Safe Hearts Plan.
Supporting Data: Why Integration Matters
The urgency of this policy shift is underscored by the current epidemiological landscape in Europe. NCDs remain the leading cause of death in the EU, and the economic burden of these conditions is estimated to cost the European economy billions of euros annually in direct healthcare expenditures and lost productivity.
The Comorbidity Crisis
Clinical data indicates that the prevalence of comorbid cardiovascular and respiratory disease is significantly higher than previously estimated. Patients suffering from COPD, for instance, are at a substantially elevated risk of developing ischemic heart disease and heart failure.
- Shared Risk Factors: Hypertension, systemic inflammation, and metabolic syndrome are common threads that connect heart and lung pathologies.
- Diagnostic Gaps: Research indicates that patients presenting with heart failure symptoms are often not screened for obstructive sleep apnoea, leading to higher hospital readmission rates and poorer long-term prognoses.
- The Power of Early Detection: The ERS highlights that by integrating targeted respiratory assessments into cardiovascular check-ups, healthcare providers can identify latent respiratory issues years before they become symptomatic or require emergency intervention.
By harmonizing these checks, the EU aims to reduce the "diagnostic odyssey" that many patients currently face, where they are bounced between cardiology and pulmonology departments without a coordinated treatment plan.
Official Responses: Voices from the Frontlines
The adoption of the report has drawn praise from policymakers and medical professionals alike, who view it as a triumph of scientific advocacy over administrative fragmentation.
Raquel Duarte, ERS Director of Scientific Affairs to the EU, issued a statement shortly after the vote:
"This vote by the European Parliament marks an important step towards strengthening cardiovascular and respiratory health together. The Safe Hearts Plan provides a valuable framework for addressing cardiovascular disease, and importantly its comorbidities and precursors across the entire health pathway—from prevention and early detection to treatment and rehabilitation."
Duarte emphasized that the focus on respiratory conditions—specifically COPD—is a "welcome" development that acknowledges the socio-economic inequalities in health outcomes. She noted that the "next step now is to ensure that the Safe Hearts Plan translates into clear and effective measures across the EU with the cooperation between European institutions, Member States, the scientific community, healthcare professionals, patients and civil society."
Health advocates have echoed these sentiments, stressing that the report provides a necessary blueprint for the European Commission to hold individual Member States accountable for the quality and accessibility of their NCD screening programs.
Implications: A New Era for European Healthcare
The ripple effects of this vote will likely be felt in healthcare systems across all 27 EU member states over the next decade.
1. Reforming Healthcare Infrastructure
Member states will be encouraged to redesign their primary care clinics to accommodate integrated diagnostic tools. This will require investment in medical technology, such as portable spirometers for cardiac clinics, and training for primary care practitioners to recognize the early warning signs of combined cardio-respiratory dysfunction.
2. Addressing Health Inequalities
The report explicitly mentions the need to address the risk factors that disproportionately affect lower-income populations. This includes stricter enforcement of air quality standards, expanded cessation programs for tobacco and nicotine products, and subsidies for screening programs in underserved regions.
3. Data-Driven Policy
By standardizing how screening data is collected and reported, the EU aims to create a more robust "health intelligence" network. This data will allow for better resource allocation, helping ministries of health identify which regions are most in need of targeted interventions.
4. A Template for Global Health
The European model of integrated NCD management is being closely watched by international health organizations. If the implementation of the Safe Hearts Plan proves successful, it may serve as a template for other regions, such as the WHO Europe region and beyond, to combat the rising tide of chronic disease through a cross-disciplinary, systemic approach.
Conclusion
The adoption of the report on cardiovascular diseases is a watershed moment for European health policy. It reflects a maturing understanding of human physiology, where the heart and lungs are viewed not as isolated systems, but as essential partners in the maintenance of human life.
As the EU moves from the legislative phase to the implementation phase, the success of this initiative will depend on the continued collaboration between the European institutions and the scientific community. For the millions of Europeans living with, or at risk of, NCDs, this integrated strategy offers a glimmer of hope: a future where the health system is as connected as the organs it seeks to protect.
For more information on the advocacy work conducted by the European Respiratory Society and the European Lung Foundation regarding this topic, please visit the ERS Advocacy and Publications portal.
